Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (14910) 14910
Publication (1884) 1884
Book Chapter (101) 101
Book Review (97) 97
Conference Proceeding (43) 43
Book / eBook (34) 34
Dissertation (9) 9
Magazine Article (8) 8
Newspaper Article (5) 5
Trade Publication Article (5) 5
Web Resource (4) 4
Newsletter (3) 3
Data Set (2) 2
Government Document (2) 2
Paper (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8706) 8706
index medicus (7395) 7395
animals (6281) 6281
poly polymerase (5669) 5669
apoptosis (5422) 5422
poly polymerases - metabolism (5274) 5274
oncology (3453) 3453
biochemistry & molecular biology (3164) 3164
mice (3130) 3130
apoptosis - drug effects (3078) 3078
cancer (2947) 2947
cell biology (2659) 2659
cell line, tumor (2612) 2612
poly polymerase inhibitors (2555) 2555
female (2454) 2454
proteins (2233) 2233
male (2193) 2193
activation (2027) 2027
dna damage (1986) 1986
poly polymerase-1 (1842) 1842
dna repair (1811) 1811
rats (1612) 1612
oxidative stress (1578) 1578
expression (1510) 1510
ribose (1507) 1507
enzyme inhibitors - pharmacology (1443) 1443
caspases - metabolism (1428) 1428
pharmacology & pharmacy (1409) 1409
inhibition (1405) 1405
cell death (1317) 1317
article (1316) 1316
research (1291) 1291
antineoplastic agents - pharmacology (1279) 1279
caspase (1260) 1260
cell line (1249) 1249
deoxyribonucleic acid--dna (1209) 1209
gene expression (1199) 1199
cell survival - drug effects (1198) 1198
dna (1192) 1192
signal transduction (1187) 1187
analysis (1184) 1184
tumors (1159) 1159
phosphorylation (1145) 1145
chemotherapy (1138) 1138
cells, cultured (1120) 1120
poly polymerases - genetics (1118) 1118
cells (1102) 1102
cell cycle (1099) 1099
breast cancer (1088) 1088
mutation (1057) 1057
death (1051) 1051
polymerase (1049) 1049
blotting, western (1020) 1020
multidisciplinary sciences (1018) 1018
kinases (1002) 1002
caspase 3 - metabolism (998) 998
research article (998) 998
cell proliferation - drug effects (993) 993
dose-response relationship, drug (988) 988
caspase-3 (986) 986
mitochondria (933) 933
inhibitors (918) 918
dna-damage (914) 914
medicine (893) 893
monosaccharides (888) 888
enzymes (886) 886
sugars (880) 880
adp (874) 874
health aspects (874) 874
in-vitro (867) 867
genetic aspects (863) 863
parp (855) 855
caspase 3 (845) 845
cell-death (821) 821
cytotoxicity (815) 815
repair (811) 811
homologous recombination (808) 808
poly (798) 798
neurosciences (796) 796
care and treatment (784) 784
biology (768) 768
enzyme activation (767) 767
tumor cells, cultured (763) 763
flow cytometry (761) 761
signal transduction - drug effects (745) 745
science (736) 736
benzamides - pharmacology (727) 727
apoptosis - physiology (724) 724
poly polymerase 1 (707) 707
reactive oxygen species - metabolism (707) 707
physiological aspects (705) 705
toxicology (700) 700
cell proliferation (696) 696
protein (689) 689
cancer therapies (685) 685
time factors (680) 680
inflammation (650) 650
nf-kappa-b (648) 648
biochemistry (646) 646
rodents (645) 645
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (24) 24
Online Resources - Online (5) 5
UTL at Downsview - May be requested (3) 3
UofT at Mississauga - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
UofT at Scarborough - Stacks (2) 2
UofT at Scarborough - Withdrawn (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (14849) 14849
Chinese (48) 48
French (38) 38
Japanese (20) 20
Russian (18) 18
German (13) 13
Polish (8) 8
Korean (7) 7
Hungarian (4) 4
Spanish (3) 3
Ukrainian (3) 3
Czech (2) 2
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Poly (ADP-Ribose) polymerase inhibitors: Recent advances and future development
by Scott, Clare L and Swisher, Elizabeth M and Kaufmann, Scott H
Journal of Clinical Oncology, ISSN 0732-183X, 04/2015, Volume 33, Issue 12, pp. 1397 - 1406
Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, especially relapsed platinum-sensitive high-grade... 
POLY(ADP-RIBOSE) POLYMERASE | SEROUS OVARIAN-CANCER | ONCOLOGY | DNA-DAMAGE RESPONSE | SECONDARY MUTATIONS | DOUBLE-STRAND BREAKS | HOMOLOGOUS-RECOMBINATION | REFRACTORY SOLID TUMORS | OLAPARIB MAINTENANCE THERAPY | NEGATIVE BREAST-CANCER | PARP INHIBITOR | Neoplasms, Glandular and Epithelial - enzymology | Clinical Trials, Phase III as Topic | Animals | Humans | Enzyme Inhibitors - pharmacology | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Female | Enzyme Inhibitors - therapeutic use | Ovarian Neoplasms - drug therapy | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | Bon | Biology of Neoplasia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
by Tutt, Andrew, Dr and Robson, Mark, MD and Garber, Judy E, MD and Domchek, Susan M, MD and Audeh, M William, MD and Weitzel, Jeffrey N, Prof and Friedlander, Michael, Prof and Arun, Banu, Prof and Loman, Niklas, MD and Schmutzler, Rita K, Prof and Wardley, Andrew, MD and Mitchell, Gillian, MD and Earl, Helena, PhD and Wickens, Mark, BSc and Carmichael, James, Prof and Onkologi och Patologi, MV and Lund University and Oncology and Pathology, MV and Lunds universitet
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9737, pp. 235 - 244
Summary Background Olaparib, a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor, induced synthetic lethality in BRCA -deficient cells. A... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | GENE | ANTHRACYCLINE | MUTANT-CELLS | DEFECT | RESISTANCE | HOMOLOGY-DIRECTED REPAIR | PHASE-II | TAXANE | TUMORS | WILD-TYPE ALLELE | Prospective Studies | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Piperazines - therapeutic use | Breast Neoplasms - drug therapy | Poly(ADP-ribose) Polymerase Inhibitors | Maximum Tolerated Dose | Phthalazines - therapeutic use | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Aged | Genes, BRCA1 | Antimitotic agents | Dosage and administration | Antineoplastic agents | Drug therapy | Testing | Ovarian cancer | Medical research | Breast cancer | Mutation | Index Medicus | Abridged Index Medicus | Anemia | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
by Audeh, M William, Dr and Carmichael, James, Prof and Penson, Richard T, MD and Friedlander, Michael, Prof and Powell, Bethan, Prof and Bell-McGuinn, Katherine M, PhD and Scott, Clare, MD and Weitzel, Jeffrey N, Prof and Oaknin, Ana, MD and Loman, Niklas, MD and Lu, Karen, Prof and Schmutzler, Rita K, Prof and Matulonis, Ursula, MD and Wickens, Mark, BSc and Tutt, Andrew, PhD and Onkologi och Patologi, MV and Lund University and Oncology and Pathology, MV and Lunds universitet
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9737, pp. 245 - 251
Summary Background Olaparib is a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in homozygous BRCA... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | THERAPY | MUTANT-CELLS | BREAKS | DEFECT | SENSITIVITY | HOMOLOGY-DIRECTED REPAIR | AZD2281 | DNA-REPAIR | TUMORS | DELETION | Prospective Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Piperazines - therapeutic use | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - genetics | Maximum Tolerated Dose | Phthalazines - therapeutic use | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Aged | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Antimitotic agents | Dosage and administration | Antineoplastic agents | Drug therapy | Testing | Ovarian cancer | Chemotherapy | Breast cancer | Mutation | Cancer therapies | Anemia | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Safety & clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with Poly (ADP-Ribose) polymerase inhibitor olaparib or vascular endothelial growth factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A dose-escalation, phase I study
by Lee, Jung-Min and Cimino-Mathews, Ashley and Peer, Cody J and Zimmer, Alexandra and Lipkowitz, Stanley and Annunziata, Christina M and Cao, Liang and Harrell, Maria I and Swisher, Elizabeth M and Houston, Nicole and Botesteanu, Dana-Adriana and Taube, Janis M and Thompson, Elizabeth and Ogurtsova, Aleksandra and Xu, Haiying and Nguyen, Jeffers and Ho, Tony W and Figg, William D and Kohn, Elise C
Journal of Clinical Oncology, ISSN 0732-183X, 07/2017, Volume 35, Issue 19, pp. 2193 - 2202
Purpose Data suggest that DNA damage by poly (ADP-ribose) polymerase inhibition and/or reduced vascular endothelial growth factor signaling by vascular... 
SENSITIVE OVARIAN-CANCER | MULTICENTER | ANTI-PD-1 | ONCOLOGY | ANTITUMOR-ACTIVITY | NIVOLUMAB | Piperazines - administration & dosage | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Genital Neoplasms, Female - drug therapy | Adult | Female | Quinazolines - administration & dosage | Piperazines - pharmacokinetics | Phthalazines - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Genital Neoplasms, Female - immunology | B7-H1 Antigen - immunology | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Genital Neoplasms, Female - metabolism | Protein Kinase Inhibitors - administration & dosage | B7-H1 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | B7-H1 Antigen - biosynthesis | Quinazolines - adverse effects | Aged | Genital Neoplasms, Female - pathology | Phthalazines - adverse effects | Lymphocytes, Tumor-Infiltrating - immunology | Index Medicus | Phase I and Clinical Pharmacology | Combined Modality | Breast Cancer | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
by Anand G. Patel and Jann N. Sarkaria and Scott H. Kaufmann and Philip C. Hanawalt
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 2/2011, Volume 108, Issue 8, pp. 3406 - 3411
Poly(ADP-ribose) polymerase (PARP) inhibitors are strikingly toxic to cells with defects in homologous recombination (HR). The mechanistic basis for these... 
Phosphorylation | Somatic cells | DNA | DNA damage | Cell lines | Medical genetics | Small interfering RNA | Genetic mutation | Genomic instability | Tumors | Chemotherapy | Synthetic lethality | Double-strand break repair | DNA repair | PROTEIN | double-strand break repair | MUTANT-CELLS | MULTIDISCIPLINARY SCIENCES | synthetic lethality | V(D)J RECOMBINATION | DOUBLE-STRAND BREAKS | TUMOR-CELLS | chemotherapy | FANCONI-ANEMIA | KINASE CATALYTIC SUBUNIT | ATM | DNA-REPAIR | BRCA-MUTATED BREAST | Cell Line | Genomic Instability | Animals | Recombination, Genetic | DNA Repair | DNA-Activated Protein Kinase - metabolism | Cell Death | Enzyme Inhibitors - pharmacology | Mice | Poly(ADP-ribose) Polymerase Inhibitors | Adenosine diphosphate | Pharmacogenetics | Research | Properties | Genetic recombination | Protein kinases | Index Medicus | Biological Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
by Sandhu, Shahneen K, MD and Schelman, William R, MD and Wilding, George, MD and Moreno, Victor, MD and Baird, Richard D, PhD and Miranda, Susana, BSc and Hylands, Lucy, BSc and Riisnaes, Ruth, FIBMS and Forster, Martin, PhD and Omlin, Aurelius, MD and Kreischer, Nathan, MSc and Thway, Khin, MD and Gevensleben, Heidrun, MD and Sun, Linda, PhD and Loughney, John, PhD and Chatterjee, Manash, PhD and Toniatti, Carlo, PhD and Carpenter, Christopher L, MD and Iannone, Robert, MD and Kaye, Stan B, Prof and de Bono, Johann S, Prof and Wenham, Robert M
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 9, pp. 882 - 892
Summary Background Poly(ADP-ribose) polymerase (PARP) is implicated in DNA repair and transcription regulation. Niraparib (MK4827) is an oral potent, selective... 
Hematology, Oncology and Palliative Medicine | OLAPARIB | EVALUATE | THERAPY | GENE | ONCOLOGY | STRATEGY | PROSTATE-CANCER | SUSCEPTIBILITY | GUIDELINES | TUMOR-CELLS | I CLINICAL-TRIALS | Prognosis | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Male | Ovarian Neoplasms - genetics | Tissue Distribution | Prostatic Neoplasms - genetics | Neoplasms - genetics | Adult | Female | Piperidines - pharmacokinetics | Ovarian Neoplasms - drug therapy | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Neoplasm Recurrence, Local - diagnosis | Mutation - genetics | Poly(ADP-ribose) Polymerase Inhibitors | Neoplasms - drug therapy | BRCA1 Protein - genetics | Maximum Tolerated Dose | Indazoles - pharmacokinetics | Piperidines - therapeutic use | Heterozygote | Neoplasm Recurrence, Local - genetics | Aged | Neoplasms - pathology | BRCA2 Protein - genetics | Indazoles - therapeutic use | Cohort Studies | Cancer patients | Analysis | Genetic aspects | Genetic transcription | Sugars | Cancer | Monosaccharides | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Pharmacologic characterization of fluzoparib, a novel poly(ADP‐ribose) polymerase inhibitor undergoing clinical trials
by Wang, Lei and Yang, Changyong and Xie, Chengying and Jiang, Jiahua and Gao, Mingzhao and Fu, Li and Li, Yun and Bao, Xubin and Fu, Haoyu and Lou, Liguang
Cancer Science, ISSN 1347-9032, 03/2019, Volume 110, Issue 3, pp. 1064 - 1075
Poly(ADP‐ribose) polymerase (PARP) enzymes play an important role in repairing DNA damage and maintaining genomic stability. Olaparib, the first‐in‐class PARP... 
toxicity | pharmacokinetics | poly(ADP‐ribose) polymerase | fluzoparib | antitumor activity | poly(ADP-ribose) polymerase | DOWN-REGULATION | OVARIAN-CANCER | COMBINATION | TUMORS | MAINTENANCE THERAPY | OLAPARIB | ONCOLOGY | DOUBLE-BLIND | AGENTS | HOMOLOGOUS RECOMBINATION | PARP INHIBITORS | Clinical trials | DNA damage | Sugars | Monosaccharides | Cell proliferation | Homologous recombination | Cytotoxicity | Metastasis | Kinases | Cancer therapies | DNA repair | Stomach cancer | Defects | Ovarian cancer | Homologous recombination repair | Enzymatic activity | Ribose | Paclitaxel | Xenografts | Drug dosages | Deoxyribonucleic acid--DNA | Enzymes | Poly(ADP-ribose) polymerase | Breast cancer | FDA approval | Poly(ADP-ribose) Polymerase 1 | Antitumor activity | Hypoxia | Software | Apoptosis | Pharmaceuticals | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
by Cherrie K. Donawho and Yan Luo and Yanping Luo and Thomas D. Penning and Joy L. Bauch and Jennifer J. Bouska and Velitchka D. Bontcheva-Diaz and Bryan F. Cox and Theodore L. DeWeese and Larry E. Dillehay and Debra C. Ferguson and Nayereh S. Ghoreishi-Haack and David R. Grimm and Ran Guan and Edward K. Han and Rhonda R. Holley-Shanks and Boris Hristov and Kenneth B. Idler and Ken Jarvis and Eric F. Johnson and Lawrence R. Kleinberg and Vered Klinghofer and Loren M. Lasko and Xuesong Liu and Kennan C. Marsh and Thomas P. McGonigal and Jonathan A. Meulbroek and Amanda M. Olson and Joann P. Palma and Luis E. Rodriguez and Yan Shi and Jason A. Stavropoulos and Alan C. Tsurutani and Gui-Dong Zhu and Saul H. Rosenberg and Vincent L. Giranda and David J. Frost
Clinical Cancer Research, ISSN 1078-0432, 05/2007, Volume 13, Issue 9, pp. 2728 - 2737
Purpose: To evaluate the preclinical pharmacokinetics and antitumor efficacy of a novel orally bioavailable poly(ADP-ribose) polymerase (PARP) inhibitor,... 
PARP | DNA-damaging agents | BRCA1 | BRCA2 | potentiation | Humans | Biological Availability | Male | Rats, Inbred Strains | Enzyme Inhibitors - administration & dosage | Benzimidazoles - administration & dosage | Enzyme Inhibitors - pharmacokinetics | Female | Disease Models, Animal | Administration, Oral | Benzimidazoles - pharmacokinetics | Rats | Mice, Inbred Strains | Poly(ADP-ribose) Polymerase Inhibitors | Blood-Brain Barrier - metabolism | Haplorhini | Neoplasms - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Drug Synergism | Xenograft Model Antitumor Assays | Animals | Dogs | Cell Line, Tumor | Mice | DNA Damage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
by Shivaani Kummar and Robert Kinders and Martin E. Gutierrez and Larry Rubinstein and Ralph E. Parchment and Lawrence R. Phillips and Jiuping Ji and Anne Monks and Jennifer A. Low and Alice Chen and Anthony J. Murgo and Jerry Collins and Seth M. Steinberg and Helen Eliopoulos and Vincent L. Giranda and Gary Gordon and Lee Helman and Robert Wiltrout and Joseph E. Tomaszewski and James H. Doroshow
Journal of Clinical Oncology, ISSN 0732-183X, 06/2009, Volume 27, Issue 16, pp. 2705 - 2711
Purpose We conducted the first phase 0 clinical trial in oncology of a therapeutic agent under the Exploratory Investigational New Drug Guidance of the US Food... 
POLY(ADP-RIBOSE) POLYMERASE | DNA-DAMAGING AGENTS | TUMOR-BIOPSIES | ONCOLOGY | MODELS | GENE | DRUG DEVELOPMENT | PARP | MICE | CANCER | Humans | Middle Aged | Biological Availability | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Feasibility Studies | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Benzimidazoles - administration & dosage | Enzyme Inhibitors - pharmacokinetics | Female | Antineoplastic Agents - pharmacokinetics | Benzimidazoles - therapeutic use | Leukocytes, Mononuclear - drug effects | Administration, Oral | Benzimidazoles - pharmacokinetics | Neoplasms - enzymology | Treatment Outcome | Enzyme Inhibitors - therapeutic use | Poly(ADP-ribose) Polymerase Inhibitors | Neoplasms - drug therapy | Biopsy | Leukocytes, Mononuclear - enzymology | Aged | Neoplasms - pathology | Research Design | Clinical Trials, Phase I as Topic | Original Reports | To2 | Bios3
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Discovery of 4′-Chloromethyl-2′-deoxy-3′,5′-di‑O‑isobutyryl-2′-fluorocytidine (ALS-8176), A First-in-Class RSV Polymerase Inhibitor for Treatment of Human Respiratory Syncytial Virus Infection
by Wang, Guangyi and Deval, Jerome and Hong, Jin and Dyatkina, Natalia and Prhavc, Marija and Taylor, Joshua and Fung, Amy and Jin, Zhinan and Stevens, Sarah K and Serebryany, Vladimir and Liu, Jyanwei and Zhang, Qingling and Tam, Yuen and Chanda, Sushmita M and Smith, David B and Symons, Julian A and Blatt, Lawrence M and Beigelman, Leo
Journal of Medicinal Chemistry, ISSN 0022-2623, 02/2015, Volume 58, Issue 4, pp. 1862 - 1878
Respiratory syncytial virus (RSV) is a leading pathogen of childhood and is associated with significant morbidity and mortality. To date, ribavirin is the only... 
DESIGN | CHEMISTRY, MEDICINAL | REPLICATION | MECHANISM | ANALOGS | NUCLEOSIDES | 4'-AZIDOCYTIDINE | ANTIVIRAL ACTIVITY | RIBAVIRIN | HEPATITIS-C | RNA-POLYMERASE | Prodrugs - administration & dosage | Deoxycytidine - chemistry | DNA-Directed RNA Polymerases - antagonists & inhibitors | Humans | Molecular Conformation | Deoxycytidine - pharmacology | Male | Respiratory Syncytial Viruses - enzymology | Prodrugs - chemistry | Structure-Activity Relationship | Deoxycytidine - chemical synthesis | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Antiviral Agents - chemistry | Respiratory Syncytial Virus Infections - drug therapy | Enzyme Inhibitors - chemistry | Respiratory Syncytial Virus Infections - virology | Virus Replication - drug effects | Antiviral Agents - pharmacology | Cricetinae | Respiratory Syncytial Viruses - drug effects | Enzyme Inhibitors - pharmacology | Rats | Antiviral Agents - administration & dosage | Drug Discovery | Poly(ADP-ribose) Polymerase Inhibitors | Rats, Sprague-Dawley | Haplorhini | Poly(ADP-ribose) Polymerases - metabolism | Animals | DNA-Directed DNA Polymerase - metabolism | DNA-Directed RNA Polymerases - metabolism | Prodrugs - pharmacology | Deoxycytidine - analogs & derivatives
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2
by Drew, Yvette and Mulligan, Evan A and Vong, Wan-Tse and Thomas, Huw D and Kahn, Samra and Kyle, Suzanne and Mukhopadhyay, Asima and Los, Gerrit and Hostomsky, Zdenek and Plummer, Elizabeth R and Edmondson, Richard J and Curtin, Nicola J
Journal of the National Cancer Institute, ISSN 0027-8874, 02/2011, Volume 103, Issue 4, pp. 334 - 346
Background Mutations in BRCA1 and BRCA2 (BRCA1/2), components of the homologous recombination DNA repair (HRR) pathway, are associated with hereditary breast... 
BREAST-CANCER | REPAIR | MAMMARY-TUMORS | HYPERMETHYLATION | ONCOLOGY | DNA-DAMAGE | IN-VIVO | SPORADIC BREAST | HISTONE H2AX | MUTATIONS | COMBINATION | Cricetulus | Humans | Transplantation, Heterologous | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Ovarian Neoplasms - genetics | Pancreatic Neoplasms - drug therapy | DNA Methylation | Neoplasms - genetics | Genes, BRCA2 | Female | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | CHO Cells | Cell Survival - drug effects | Cricetinae | Enzyme Inhibitors - pharmacology | Gene Silencing | Pancreatic Neoplasms - genetics | Breast Neoplasms - drug therapy | Poly(ADP-ribose) Polymerase Inhibitors | Neoplasms - drug therapy | Poly(ADP-ribose) Polymerases - metabolism | Animals | Breast Neoplasms - genetics | Mice, Nude | Cell Line, Tumor | Mice | Mutation | Carboplatin - pharmacology | Antimitotic agents | Usage | BRCA mutations | Pancreatic cancer | Genetic aspects | Research | Antineoplastic agents | Drug therapy | Health aspects | Risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights